SPY416.07+3.90 0.95%
DIA341.30+3.18 0.94%
IXIC13,950.22+163.95 1.19%

VolitironRx Highlights Poster Presentation 'Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis'

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans

· 03/17/2021 08:13

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a private company that has an abstract released today at the International Society for Apheresis meeting (e-ISFA), which is being held virtually this year.

The poster presentation entitled "Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis" given by Dr. Andrew Aswani, Consultant in Intensive Care Medicine & Anesthesia at a leading London Hospital and Chief Medical Officer of Santersus AG, includes data showing that Nu.Q® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps ("NETs") in sepsis.

Commenting on the data Dr. Aswani said, "Our data indicated that the Nu.Q® assay may have wide applicability to monitor the treatment of diseases with a NET component and potentially may also be used for patient selection. This is especially important given the wide range of diseases where NETosis plays a role such as COVID-19, sepsis, autoimmune diseases and cancer. Santersus has already begun the next phase of studies that are also using Volition's Nu.Q® assays, including our first human trial, and we look forward to sharing the results in the coming months."

Dr. Jake Micallef, Volition's Chief Scientific Officer added, "Santersus' highly selective plasmapheresis treatment is demonstrably effective in the removal of up to 99% of circulating NETs from animals in septic shock as measured by our Nu.Q® NETs assay. The results also show that the treatment leads to a stabilization of NETs in circulation and a great improvement in the well-being of the treated animal. This is the first study reported to use Volition's simple, low-cost Nu.Q® immunoassays to monitor response to a treatment."

 

To watch a short video of Dr. Jake Micallef commenting on this study click https://youtu.be/5sm3Z6dmr6w.

To view the presentation given by Dr. Aswani click here or download the poster here.